Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1442-1452

  Elsworth, John D ^a   Groman, Stephanie M ^b   Jentsch, J David ^b   Valles, Rodrigo ^a   Shahid, Mohammed ^c   Wong, Erik ^d   Marston, Hugh ^c   Roth, Robert H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Newhouse   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

Asenapine; Cognitive function; Phencyclidine; Primate; Schizophrenia; Serotonin

Indexed keywords

ASENAPINE; DOPAMINE; MONOAMINE; PHENCYCLIDINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CENTRAL NUCLEUS (AMYGDALA); CHLOROCEBUS; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOLECULAR DYNAMICS; MOTOR PERFORMANCE; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; STEADY STATE; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; CERCOPITHECUS AETHIOPS; COGNITION DISORDERS; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; PHENCYCLIDINE; PSYCHOMOTOR PERFORMANCE; REVERSAL LEARNING; TREATMENT OUTCOME;

EID: 84856089041     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.08.026     Document Type: Article

References (96)

1. Z. Abdul-Monim, G.P. Reynolds, and J.C. Neill The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm Behav. Brain Res. 169 2006 263 273
2. R.M. Allen, and S.J. Young Phencyclidine-induced psychosis Am. J. Psychiatry 135 1978 1081 1084 (Pubitemid 8395441)
3. J.D. Andersen, and B. Pouzet Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine Neuropsychopharmacology 29 2004 1080 1090 (Pubitemid 38670046)
4. A.R. Aron, and R.A. Poldrack Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus J. Neurosci. 26 2006 2424 2433 (Pubitemid 44699002)
5. A.R. Aron, T.W. Robbins, and R.A. Poldrack Inhibition and the right inferior frontal cortex Trends Cogn. Sci. 8 2004 170 177 (Pubitemid 38429927)
6. A. Balla, R. Koneru, J. Smiley, H. Sershen, and D.C. Javitt Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release Neuropsychopharmacology 25 2001 157 164 (Pubitemid 32566337)
7. H.A. Berlin, E.T. Rolls, and U. Kischka Impulsivity, time perception, emotion and reinforcement sensitivity in patients with orbitofrontal cortex lesions Brain 127 2004 1108 1126 (Pubitemid 38623046)
8. V. Boulougouris, J.W. Dalley, and T.W. Robbins Effects of orbitofrontal, infralimbic and prelimbic cortical lesions on serial spatial reversal learning in the rat Behav. Brain Res. 179 2007 219 228 (Pubitemid 46497457)
9. V. Boulougouris, J.C. Glennon, and T.W. Robbins Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats Neuropsychopharmacology 33 2008 2007 2019 (Pubitemid 351832598)
10. R.N. Cardinal, D.R. Pennicott, C.L. Sugathapala, T.W. Robbins, and B.J. Everitt Impulsive choice induced in rats by lesions of the nucleus accumbens core Science 292 2001 2499 2501 (Pubitemid 32601663)
11. S.A. Castner, P.S. Goldman-Rakic, and G.V. Williams Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia Psychopharmacology (Berl) 174 2004 111 125 (Pubitemid 38925096)
12. Y. Chudasama, and T.W. Robbins Dissociable contributions of the orbitofrontal and infralimbic cortex to pavlovian autoshaping and discrimination reversal learning: further evidence for the functional heterogeneity of the rodent frontal cortex J. Neurosci. 23 2003 8771 8780 (Pubitemid 37176658)
13. H.F. Clarke, J.W. Dalley, H.S. Crofts, T.W. Robbins, and A.C. Roberts Cognitive inflexibility after prefrontal serotonin depletion Science 304 2004 878 880 (Pubitemid 38620188)
14. H.F. Clarke, S.C. Walker, H.S. Crofts, J.W. Dalley, T.W. Robbins, and A.C. Roberts Prefrontal serotonin depletion affects reversal learning but not attentional set shifting J. Neurosci. 25 2005 532 538 (Pubitemid 40105626)
15. H.F. Clarke, S.C. Walker, J.W. Dalley, T.W. Robbins, and A.C. Roberts Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific Cereb. Cortex 17 2007 18 27 (Pubitemid 44973891)
16. J.T. Coull, B.J. Sahakian, and J.R. Hodges The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type Psychopharmacology (Berl) 123 1996 239 249 (Pubitemid 26072837)
17. A. Crider Perseveration in schizophrenia Schizophr Bull. 23 1997 63 74 (Pubitemid 27087907)
18. A. Deschenes, S. Goulet, and F.Y. Dore Rule shift under long-term PCP challenge in rats Behav. Brain Res. 167 2006 134 140 (Pubitemid 43063148)
19. P. Devoto, G. Flore, G. Longu, L. Pira, and G.L. Gessa Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex Synapse 50 2003 200 205 (Pubitemid 37315350)
20. R. Dias, T.W. Robbins, and A.C. Roberts Dissociation in prefrontal cortex of affective and attentional shifts Nature 380 1996 69 72 (Pubitemid 26076238)
21. J.D. Elsworth, A.Y. Deutch, D.E. Redmond Jr.; J.R. Taylor, J.R. Sladek Jr.; and R.H. Roth Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated primates: biochemical changes in striatal regions Neuroscience 33 1989 323 331 (Pubitemid 20039715)
22. J.D. Elsworth, M.S. Brittan, J.R. Taylor, J.R. Sladek Jr.; M.S. al-Tikriti, Y. Zea-Ponce, R.B. Innis, D.E. Redmond Jr.; and R.H. Roth Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys Cell Transplant 5 1996 315 325 (Pubitemid 26096191)
23. European Medicines Agency Sycrest (Asenapine) 2010 http://www.ema.europa. eu/ema/index.jsp%3fcurl=pages/medicines/human/medicines/001177/human-med-001379. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124& jsenabled=true
24. L.K. Fellows, and M.J. Farah Ventromedial frontal cortex mediates affective shifting in humans: evidence from a reversal learning paradigm Brain 126 2003 1830 1837 (Pubitemid 36917342)
25. P.J. Fletcher, C.C. Tenn, Z. Rizos, V. Lovic, and S. Kapur Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex Psychopharmacology (Berl) 183 2005 190 200 (Pubitemid 41609271)
26. S.B. Floresco, M.A. Geyer, L.H. Gold, and A.A. Grace Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia Schizophr Bull. 31 2005 888 894 (Pubitemid 41437783)
27. O. Franberg, M.M. Marcus, V. Ivanov, B. Schilstrom, M. Shahid, and T.H. Svensson Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms Psychopharmacology (Berl) 204 2009 251 264
28. M.J. Frank, and E.D. Claus Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal Psychol. Rev. 113 2006 300 326 (Pubitemid 43815199)
29. M.F. Green, and D.L. Braff Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications Biol. Psychiatry 49 2001 374 384 (Pubitemid 32182368)
30. P.J. Gresch, A.F. Sved, M.J. Zigmond, and J.M. Finlay Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex J. Neurochem. 65 1995 111 116
31. F. Grossman, W.Z. Potter, E.A. Brown, and G. Maislin A double-blind study comparing idazoxan and bupropion in bipolar depressed patients J. Affect Disord. 56 1999 237 243 (Pubitemid 30058228)
32. J.J. Hagan, and D.N. Jones Predicting drug efficacy for cognitive deficits in schizophrenia Schizophr Bull. 31 2005 830 853 (Pubitemid 41437777)
33. K. Hashimoto, Y. Fujita, E. Shimizu, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol Eur. J. Pharmacol. 519 2005 114 117 (Pubitemid 43181173)
34. K. Hashimoto, Y. Fujita, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors Neuropsychopharmacology 32 2007 514 521
35. P. Hertel, M.V. Fagerquist, and T.H. Svensson Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade Science 286 1999 105 107 (Pubitemid 29484485)
36. P. Hertel, G.G. Nomikos, and T.H. Svensson Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level Eur. J. Pharmacol. 371 1999 153 158 (Pubitemid 29216997)
37. S.D. Iversen, and M. Mishkin Perseverative interference in monkeys following selective lesions of the inferior prefrontal convexity Exp. Brain Res. 11 1970 376 386
38. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225 (Pubitemid 29067401)
39. J.D. Jentsch, and J.R. Taylor Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats Neuropsychopharmacology 24 2001 66 74
40. J.D. Jentsch, J.D. Elsworth, D.E. Redmond Jr.; and R.H. Roth Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966 J. Neurosci. 17 1997 1769 1775 (Pubitemid 27089821)
41. J.D. Jentsch, D.E. Redmond Jr.; J.D. Elsworth, J.R. Taylor, K.D. Youngren, and R.H. Roth Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine Science 277 1997 953 955 (Pubitemid 27366680)
42. J.D. Jentsch, A. Tran, D. Le, K.D. Youngren, and R.H. Roth Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat Neuropsychopharmacology 17 1997 92 99
43. J.D. Jentsch, J.D. Elsworth, J.R. Taylor, D.E. Redmond Jr.; and R.H. Roth Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia Adv. Pharmacol. 42 1998 810 814
44. J.D. Jentsch, A. Wise, Z. Katz, and R.H. Roth Alpha-noradrenergic receptor modulation of the phencyclidine- and delta9-tetrahydrocannabinol- induced increases in dopamine utilization in rat prefrontal cortex Synapse 28 1998 21 26 (Pubitemid 128770599)
45. J.D. Jentsch, J.R. Taylor, J.D. Elsworth, D.E. Redmond Jr.; and R.H. Roth Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits Neuroscience 90 1999 823 832 (Pubitemid 29156748)
46. J.D. Jentsch, R.H. Roth, and J.R. Taylor Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity Biol. Psychiatry 48 2000 415 424
47. J.D. Jentsch, P. Olausson, R. De La Garza, and J.R. Taylor Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys Neuropsychopharmacology 26 2002 183 190 (Pubitemid 34093081)
48. J.D. Jentsch, D. Sanchez, J.D. Elsworth, and R.H. Roth Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype Brain Res. 1246 2008 41 46
49. J.D. Jentsch Pre-clinical models of cognitive dysfunction in schizophrenia: new avenues to addressing unmet needs Clin. Neurosci. Res. 3 2003 303 315
50. S. Kalkstein, I. Hurford, and R.C. Gur Neurocognition in schizophrenia Curr. Top. Behav. Neurosci. 4 2010 373 390
51. A. Klingner, T.A. Ban, and H.E. Lehmann Transference, discrimination and reversal. A comparison between normals and pathological groups Cond Reflex 7 1972 216 225
52. B. Kopp, and F. Rist Error-correcting behavior in schizophrenic patients Schizophr Res. 13 1994 11 22 (Pubitemid 24227893)
53. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
54. H.Y. Lane, C.C. Lee, Y.C. Liu, and W.H. Chang Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics Pharmacogenomics 6 2005 139 149
55. V. Laurent, and J. Podhorna Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task Behav. Pharmacol. 15 2004 141 148 (Pubitemid 38582280)
56. B. Lee, S.M. Groman, E.D. London, and J.D. Jentsch Dopamine D2/D3 receptors play a specific role in the reversal of a learned visual discrimination in monkeys Neuropsychopharmacology 32 2007 2125 2134 (Pubitemid 47417686)
57. D.A. Lewis, and P. Levitt Schizophrenia as a disorder of neurodevelopment Annu. Rev. Neurosci. 25 2002 409 432 (Pubitemid 34748023)
58. R.E. Litman, T.P. Su, W.Z. Potter, W.W. Hong, and D. Pickar Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine Br. J. Psychiatry 168 1996 571 579
59. D.S. Majid, W. Cai, J.S. George, F. Verbruggen, and A.R. Aron Transcranial magnetic stimulation reveals dissociable mechanisms for global versus selective corticomotor suppression underlying the stopping of action Cereb. Cortex 2011
60. A.K. Malhotra, D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar, and A. Breier NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 14 1996 301 307 (Pubitemid 26151927)
61. A.K. Malhotra, D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar, and A. Breier Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics Neuropsychopharmacology 17 1997 141 150 (Pubitemid 27365955)
62. M.M. Marcus, C. Wiker, O. Franberg, A. Konradsson-Geuken, X. Langlois, K. Jardemark, and T.H. Svensson Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission Int. J. Neuropsychopharmacol. 13 2010 891 903
63. J.P. Marquis, S. Goulet, and F.Y. Dore Schizophrenia-like syndrome inducing agent phencyclidine failed to impair memory for temporal order in rats Neurobiol. Learn. Mem. 80 2003 158 167 (Pubitemid 36970237)
64. D. Masaki, C. Yokoyama, S. Kinoshita, H. Tsuchida, Y. Nakatomi, K. Yoshimoto, and K. Fukui Relationship between limbic and cortical 5-HT neurotransmission and acquisition and reversal learning in a go/no-go task in rats Psychopharmacology (Berl) 189 2006 249 258 (Pubitemid 44691546)
65. H.Y. Meltzer, and M. Huang In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems Prog. Brain Res. 172 2008 177 197
66. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172 (Pubitemid 37464960)
67. H.Y. Meltzer Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia Psychopharmacology (Berl) Suppl. 99 1989 S18 S27
68. ® 2010 http://www.saphris.com/
69. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, T. Hershey, S. Craft, and J.W. Olney Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 1999 106 118 (Pubitemid 29010370)
70. Y. Noda, H. Kamei, T. Mamiya, H. Furukawa, and T. Nabeshima Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions Neuropsychopharmacology 23 2000 375 387
71. R.D. Oades Stimulus dimension shifts in patients with schizophrenia, with and without paranoid hallucinatory symptoms, or obsessive compulsive disorder: strategies, blocking and monoamine status Behav. Brain Res. 88 1997 115 131 (Pubitemid 27459699)
72. S.G. Potkin, M. Cohen, and J. Panagides Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial J. Clin. Psychiatry 68 2007 1492 1500 (Pubitemid 350073395)
73. J.M. Rainey Jr.; and M.K. Crowder Prolonged psychosis attributed to phencyclidine: report of three cases Am. J. Psychiatry 132 1975 1076 1078
74. G.P. Reynolds, Z. Yao, X. Zhang, J. Sun, and Z. Zhang Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response Eur. Neuropsychopharmacol. 15 2005 143 151 (Pubitemid 40193419)
75. T.W. Robbins, and A.C. Roberts Differential regulation of fronto-executive function by the monoamines and acetylcholine Cereb. Cortex 17 Suppl. 1 2007 i151 i160
76. T.W. Robbins Synthesizing schizophrenia: a bottom-up, symptomatic approach Schizophr Bull. 31 2005 854 864 (Pubitemid 41437778)
77. J.S. Rodefer, E.R. Murphy, and M.G. Baxter PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats Eur. J. Neurosci. 21 2005 1070 1076 (Pubitemid 40461058)
78. R.D. Rogers, T.C. Andrews, P.M. Grasby, D.J. Brooks, and T.W. Robbins Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans J. Cogn. Neurosci. 12 2000 142 162 (Pubitemid 30142790)
79. E.T. Rolls The functions of the orbitofrontal cortex Brain Cogn. 55 2004 11 29 (Pubitemid 38591427)
80. B.J. Sahakian, J.J. Coull, and J.R. Hodges Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type J. Neurol. Neurosurg. Psychiatry 57 1994 120 121 (Pubitemid 24030923)
81. G. Schoenbaum, S.L. Nugent, M.P. Saddoris, and B. Setlow Orbitofrontal lesions in rats impair reversal but not acquisition of go, no-go odor discriminations Neuroreport 13 2002 885 890 (Pubitemid 34492920)
82. K. Schwabe, S. Klein, and M. Koch Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats Behav. Brain Res. 168 2006 150 160 (Pubitemid 43152063)
83. J.S. Schwartzbaum, and P.J. Donovick Discrimination reversal and spatial alternation associated with septal and caudate dysfunction in rats J. Comp. Physiol. Psychol. 65 1968 83 92
84. M. Shahid, G. Walker, S. Zorn, and E. Wong Asenapine: a novel psychopharmacologic agent with a unique human receptor signature J. Psychopharmacol. 23 2009 65 73
85. M.R. Stefani, and B. Moghaddam Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat Behav. Brain Res. 134 2002 267 274 (Pubitemid 34912706)
86. M.R. Stefani, and B. Moghaddam Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia Biol. Psychiatry 57 2005 433 436 (Pubitemid 40215775)
87. C.E. Stern, and R.E. Passingham The nucleus accumbens in monkeys (Macaca fascicularis). III. Reversal learning Exp. Brain Res. 106 1995 239 247
88. M.A. Taffe, S.A. Davis, T. Gutierrez, and L.H. Gold Ketamine impairs multiple cognitive domains in rhesus monkeys Drug Alcohol Depend 68 2002 175 187 (Pubitemid 35247789)
89. J.R. Taylor, J.D. Elsworth, R.H. Roth, J.R. Sladek Jr.; and D.E. Redmond Jr. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys Brain 113 1990 617 637 (Pubitemid 20222322)
90. M.S. Thomsen, H.H. Hansen, and J.D. Mikkelsen Opposite effect of phencyclidine on activity-regulated cytoskeleton-associated protein (Arc) in juvenile and adult limbic rat brain regions Neurochem. Int. 56 2010 270 275
91. H. Tsukada, S. Nishiyama, D. Fukumoto, K. Sato, T. Kakiuchi, and E.F. Domino Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys Neuropsychopharmacology 30 2005 1861 1869 (Pubitemid 41486411)
92. D. Umbricht, L. Schmid, R. Koller, F.X. Vollenweider, D. Hell, and D.C. Javitt Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia Arch. Gen. Psychiatry 57 2000 1139 1147
93. S.C. Walker, Y.P. Mikheenko, L.D. Argyle, T.W. Robbins, and A.C. Roberts Selective prefrontal serotonin depletion impairs acquisition of a detour-reaching task Eur. J. Neurosci. 23 2006 3119 3123 (Pubitemid 43882892)
94. J.D. Wallis, R. Dias, T.W. Robbins, and A.C. Roberts Dissociable contributions of the orbitofrontal and lateral prefrontal cortex of the marmoset to performance on a detour reaching task Eur. J. Neurosci. 13 2001 1797 1808 (Pubitemid 32488069)
95. J.A. Waltz, and J.M. Gold Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction Schizophr Res. 93 2007 296 303 (Pubitemid 46817948)
96. C.A. Winstanley, C. Baunez, D.E. Theobald, and T.W. Robbins Lesions to the subthalamic nucleus decrease impulsive choice but impair autoshaping in rats: the importance of the basal ganglia in Pavlovian conditioning and impulse control Eur. J. Neurosci. 21 2005 3107 3116 (Pubitemid 40917073)